BeiGene, Ltd. Sponsored ADR
(NASDAQ : BGNE)

( )
BGNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.31%86.001.3%$1325.78m
AMGNAmgen Inc.
-0.93%201.981.2%$608.04m
GILDGilead Sciences, Inc.
-0.91%68.550.9%$534.22m
LOXOLoxo Oncology Inc
0.12%233.7812.7%$511.41m
BIIBBiogen Inc.
0.46%338.961.3%$413.85m
VRTXVertex Pharmaceuticals Incorporated
-0.42%193.881.9%$324.40m
ILMNIllumina, Inc.
-2.92%303.623.5%$304.88m
REGNRegeneron Pharmaceuticals, Inc.
-3.36%404.752.6%$294.14m
ALXNAlexion Pharmaceuticals, Inc.
-2.36%114.292.0%$213.93m
INCYIncyte Corporation
-1.39%77.332.5%$145.56m
AAgilent Technologies, Inc.
-0.89%71.291.5%$145.13m
EXASExact Sciences Corporation
-3.46%76.0725.3%$135.78m
SRPTSarepta Therapeutics, Inc.
-2.05%120.2815.4%$130.09m
LGNDLigand Pharmaceuticals Incorporated
-4.23%112.9123.1%$119.15m
NBIXNeurocrine Biosciences, Inc.
-0.27%91.285.1%$97.05m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.